Although IDH mutations and MGMT methylation status are both molecular markers used in the diagnosis and treatment of gliomas, it is important to acknowledge that discrepancies in reported molecular markers for all patients may be due to changes in testing and classification guidelines over past years with older studies not reporting IDH mutation and MGMT methylation status as part of the analysis. This evidence concerns the gene MGMT and glioma.